Effects of T3 analogue Triac on caregiver-reported patient-centered outcome measures in patients with MCT8 deficiency: post-hoc analysis of an international, phase 2 trial
Year: 2026
Type: article
Abstract: Background Monocarboxylate transporter 8 (MCT8) deficiency is a rare neurodevelopmental and metabolic disorder caused by mutations in thyroid hormone transporter MCT8. Triac Trial I showed that T3 analogue Triac effectively alleviates peripheral thyrotoxicosis. However, the effects of Triac on patient-centered outcome measures are unknown. Here, we investigated relevant health outcomes, from a caregiver's perspective, that have direct impacts on the daily lives of patients and families. Methods We performed post-hoc analyses on caregiver-reported patient-centered outcome measures from Triac Trial I. This trial was an international, multicenter, phase II, single-arm, open-label trial conducted between October 2014 and June 2017. Adult and paediatric patients who completed ≥12 months of treatment with Triac were included. Semi-structured interviews were held with caregivers during all visits, assessing disease specific features and their changes. The primary objective was to identify the caregiver-reported features that showed the most prominent changes following 12 months of Triac treatment. This question ("What are the most prominent changes that the parents have observed upon Triac treatment?") was phrased open-ended to caregivers, allowing multiple observations, including both positive and negative responses. Secondary objectives were changes in syndrome-specific features and willingness to continue Triac treatment. The Triac Trial I was registered with ClinicalTrials.gov (NCT02060474). Findings In total, 40 patients were included. The median age at baseline was 7.1 years (range 1.6–66.8) and all participants were male. Caregivers of 39/40 patients (98%) reported a median of three (range 1–10) prominent changes on this open-ended question. Data on the most prominent change was not available for one patient. The most prominent changes reported by caregivers were improved interaction (23/39), alertness (16/39), motor skills (13/39), body weight (11/39) and sleep (8/39). Compared with baseline, excessive perspiration (9% vs. 49%, p < 0.0004) and constipation (42% vs. 61%, p < 0.023) were reportedly reduced after 12 months of treatment, and the proportion of patients with a sleep pattern perceived by caregivers as ‘normal' increased (92% vs. 67%, p < 0.041). Caregivers of all patients (40/40) preferred Triac continuation after trial completion. Interpretation In this exploratory post-hoc analysis of paediatric and adult patients with MCT8 deficiency, Triac improved caregiver-reported outcomes that are relevant to the daily lives of patients assessed. Although we did not assess caregiver-reported outcomes using validated clinical criteria, these data support existing positive findings of Triac on clinical and biochemical outcomes, recent approval by the European Medicines Agency and US Food and Drug Administration, and support beneficial effects on relevant disease features. Funding Dutch Scientific Organization, Sherman Foundation, NeMO Foundation, Wellcome Trust, UK National Institute for Health Research Cambridge Biomedical Centre, Toulouse University Hospital, and Una Vita Rara ONLUS.
Source: EClinicalMedicine
Authors: Matthijs E.T. Freund, Floor van der Most, Ferdy S. van Geest, Robin P. Peeters, Carla Moran, Athanasia Stoupa, Françoise Auriol, Davide Tonduti, Alice Dica, Laura Paone, Jana Krenek Malikova, Adriana van der Walt, Irenaeus F.M. de Coo, Anne McGowan, Greta Lyons, Femke K. Aarsen, Diana Barca, Marieke M. van der Knoop, Jurgen Jansen, Roelineke J. Lunsing, Paul Vrijmoeth, Marie-Claire Y. de Wit, Nicole I. Wolf, Marco Medici, Enrico S. Bertini, Sylvia Depoorter, Jan Lebl, Marco Cappa, Dana Craiu, Federica Zibordi, Isabelle Oliver Petit, Michel Polak, Krishna Chatterjee, W. Edward Visser, Stefan Groeneweg
Institutions: Erasmus MC, University of Cambridge, Addenbrooke's Hospital, Hôpital Necker-Enfants Malades, Institut des Maladies Génétiques Imagine, Centre Hospitalier Universitaire de Toulouse, University of Milan, Ospedale dei Bambini Vittore Buzzi, Carol Davila University of Medicine and Pharmacy, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Charles University, University Hospital in Motol, Fakultní nemocnice Motol a Homolka, Maastricht University, Erasmus MC - Sophia Children’s Hospital, Princess Máxima Center, Meander Medisch Centrum, University Medical Center Groningen, University of Groningen, Emma Kinderziekenhuis, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Fondazione Bambino Gesù, AZ Sint-Jan, Fondazione IRCCS Istituto Neurologico Carlo Besta
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: MCT8 deficiency, triac, thyroid hormone transporters, patient-centered outcome measures, caregiver-reported outcomes, neurodevelopmental disorders, medication adherence, sleep disorders, constipation, sweating, motor skills, alertness, social interaction, rare metabolic disorders, safety and tolerability, long-term treatment outcomes
Open Access status: gold
Estimated APC paid: $5,780
Funders: Wellcome Trust, ZonMw
OpenAlex ID: W7236596225
